These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21505303)

  • 21. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
    Ceccherini-Silberstein F; Van Baelen K; Armenia D; Trignetti M; Rondelez E; Fabeni L; Scopelliti F; Pollicita M; Van Wesenbeeck L; Van Eygen V; Dori L; Sarmati L; Aquaro S; Palamara G; Andreoni M; Stuyver LJ; Perno CF
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3938-48. PubMed ID: 20479206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
    Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Resistance to integrase inhibitors].
    Garrido C; de Mendoza C; Soriano V
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():40-6. PubMed ID: 19572425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
    Reuman EC; Bachmann MH; Varghese V; Fessel WJ; Shafer RW
    Antimicrob Agents Chemother; 2010 Feb; 54(2):934-6. PubMed ID: 19917747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
    Bar-Magen T; Sloan RD; Donahue DA; Kuhl BD; Zabeida A; Xu H; Oliveira M; Hazuda DJ; Wainberg MA
    J Virol; 2010 Sep; 84(18):9210-6. PubMed ID: 20610719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    Yotsumoto M; Hachiya A; Ichiki A; Amano K; Kinai E
    AIDS; 2020 Nov; 34(14):2155-2157. PubMed ID: 32932342
    [No Abstract]   [Full Text] [Related]  

  • 29. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.
    Reigadas S; Masquelier B; Calmels C; Laguerre M; Lazaro E; Vandenhende M; Neau D; Fleury H; Andréola ML
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3187-94. PubMed ID: 21576445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
    Van Baelen K; Van Eygen V; Rondelez E; Stuyver LJ
    AIDS; 2008 Sep; 22(14):1877-80. PubMed ID: 18753927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
    Grobler JA; Hazuda DJ
    Curr Opin Virol; 2014 Oct; 8():98-103. PubMed ID: 25128610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
    Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
    AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Johnson BC; Métifiot M; Pommier Y; Hughes SH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
    Margot NA; Ram RR; White KL; Abram ME; Callebaut C
    J Med Virol; 2019 Dec; 91(12):2188-2194. PubMed ID: 31389026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.